Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis - PubMed
a day ago
- #Type 2 diabetes mellitus
- #GLP-1 receptor agonists
- #Obesity-related cancers
- GLP-1 receptor agonists (GLP-1RAs) are widely used for Type 2 diabetes mellitus (T2DM) and obesity.
- A systematic review and meta-analysis assessed the association between GLP-1RA use and obesity-related cancers.
- The study included 24 studies with 3,960,974 patients.
- GLP-1RA use was associated with a significantly lower overall risk of obesity-related cancers within ten years (RR 0·70, 95% CI 0·54-0·89).
- Reduced risks were observed for hepatocellular carcinoma, colorectal, pancreatic, endometrial, esophageal, gallbladder, ovarian cancers, and multiple myeloma.
- No significant association was found for thyroid cancer.
- Prospective studies are needed to validate these findings and clarify underlying mechanisms.